Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism of nucleolar/nucleoplasmic partitioning of topoisomerase I

被引:36
作者
Christensen, MO
Krokowski, RM
Barthelmes, HU
Hock, R
Boege, F
Mielke, C
机构
[1] Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany
[2] Univ Wurzburg, Bioctr, Dept Cell & Dev Biol, D-97074 Wurzburg, Germany
关键词
D O I
10.1074/jbc.M400498200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase I is mostly nucleolar, because it plays a preeminent role in ribosomal DNA ( rDNA) transcription. It is cleared from nucleoli following exposure to drugs stabilizing covalent DNA intermediates of the enzyme ( e. g. camptothecin) or inhibiting RNA polymerases ( e. g. actinomycin D), an effect summarily attributed to blockade of rDNA transcription. Here we show that two distinct mechanisms are at work: ( i) Both drugs induce inactivation and segregation of the rRNA transcription machinery. With actinomycin D this leads to a co- migration of RNA- polymerase I and topoisomerase I to the nucleolar perimeter. The process has a slow onset (> 20 min), is independent of topoisomerase I activity, but requires the N- terminal domain of the enzyme to colocalize with RNA polymerase I. ( ii) Camptothecin induces, in addition, immobilization of active topoisomerase I on genomic DNA resulting in rapid nucleolar clearance and spreading of the enzyme to the entire nucleoplasm. This effect is independent of the state of rRNA transcription, involves segregation of topoisomerase I from RNA polymerase I, has a rapid onset (< 1 min), and requires catalytic activity but neither the N- terminal domain of topoisomerase I nor its major sumoylation site. Thus, nucleolar/ nucleoplasmic partitioning of topoisomerase I is regulated by interactions with RNA polymerase I and DNA but not by sumoylation.
引用
收藏
页码:21873 / 21882
页数:10
相关论文
共 45 条
[1]  
BEIDLER DR, 1995, MOL PHARMACOL, V47, P907
[2]  
Buckwalter CA, 1996, CANCER RES, V56, P1674
[3]   To be or not to be in the nucleolus [J].
Carmo-Fonseca, M ;
Mendes-Soares, L ;
Campos, I .
NATURE CELL BIOLOGY, 2000, 2 (06) :E107-E112
[4]   DNA topoisomerases: Structure, function, and mechanism [J].
Champoux, JJ .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :369-413
[5]  
Chen HK, 1999, MOL CELL BIOL, V19, P8536
[6]  
Cheutin T, 2002, J CELL SCI, V115, P3297
[7]   Dynamics of human DNA topoisomerases IIα and IIβ in living cells [J].
Christensen, MO ;
Larsen, MK ;
Barthelmes, HU ;
Hock, R ;
Andersen, CL ;
Kjeldsen, E ;
Knudsen, BR ;
Westergaard, O ;
Boege, F ;
Mielke, C .
JOURNAL OF CELL BIOLOGY, 2002, 157 (01) :31-44
[8]   Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro [J].
Christensen, MO ;
Barthelmes, HU ;
Boege, F ;
Mielke, C .
NUCLEIC ACIDS RESEARCH, 2003, 31 (24) :7255-7263
[9]   Changes in mobility account for camptothecin-induced subnuclear relocation of topoisomerase I [J].
Christensen, MO ;
Barthelmes, HU ;
Feineis, S ;
Knudsen, BR ;
Andersen, AH ;
Boege, F ;
Mielke, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (18) :15661-15665
[10]   The N-terminal domain anchors human topoisomerase I at fibrillar centers of nucleoli and nucleolar organizer regions of mitotic chromosomes [J].
Christensen, MO ;
Barthelmes, HU ;
Boege, F ;
Mielke, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) :35932-35938